Sloan-kettering Institute for Cancer Research

Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

American Cyanamid Company

Yeda Research and Develpment & Co. Ltd

Johnson & Johnson Consumer Companies, Inc.

Magdalena G Eisinger

Allen B Reitz

Carlos Plata-Salaman

Boyu Zhao

Virginia L Smith-Swintosky

Louis J Fitzpatrick

Kevin Pan

Daniel H Lee

Fa Zhang

Avner Yayon

Alan N Houghton

Peter Bohlen

Lloyd Old

Anthony P Albino

Andrew P Seddon

Olga Marko

John M Hefton

J Gregory Cairncross

Luyuan Li

The present invention is directed to the use of a compound of formula (I) 

Methods for the treatment of dermatological disorders

The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.

1,2,4-thiadiazolium derivatives as melanocortin receptor modulators

The present invention is directed to novel 1,2,4-thiadiazole derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.

1,2,4-thiadiazole derivatives as melanocortin receptor modulators

This invention provides a composition capable of stimulating growth and regeneration of epidermal cells. The composition comprises an aqueous, cell-free extract derived from epidermal cells.

Epidermal cell extracts and method to enhance wound healing and

Structural analogues of fibroblast growth factors have an amino acid sequence replacement in the ninth or tenth .beta.-strand of the factor, or the sequence that corresponds to the surface loop that connects the ninth and tenth .beta.-strands, such that the folding of the molecule is not significantly perturbed. Preferred analogues have the amino acid sequence replacement in the surface loop that extends from the ninth .beta.-strand to the tenth .beta.-strand and have the overall secondary and tertiary structure of the original factor, and bind to heparin and a member or members of the fibroblast growth factor receptor family with high affinity. In some embodiments, the analogues are prepared by replacing the surface loop sequence that connects the ninth and tenth .beta.-strand with another amino acid sequence such as a loop sequence from another structurally related fibroblast growth factor or an interleukin. Preferred analogues exhibit different biological properties and/or receptor binding specificity profiles from native factors.

Surface loop structural analogues of fibroblast growth factors

Monoclonal antibodies were discovered which recognize differentiation antigens on melanocytes and melanoma cells at various stages of differentiation. A system of classification based on these antigens is proposed and their use in the diagnosis and treatment of melanoma is given.

Monoclonal antibodies against melanocytes

Human melanocyte cells are grown in tissue culture medium containing fibroblast growth suppressor plus tumor growth promoters at pH 7.2 to about 7.4. In a stepwise procedure, Langerhans, keratinocytes and most fibroblasts are removed in the presence of the above suppressor and promoter followed by a subsequent trypsinization treatment. In a final purification step, remaining fibroblasts are separated from the melanocytes by reacting the cell mixture with monoclonal antibody specific for melanocytes, and then separating out the melanocytes from the fibroblasts on density gradients.

Method for obtaining pure, stable tissue cultures of human melanocytes

Burn victims are treated with human epidermis cells grown in tissue culture by separating the epidermis in human skin from the dermis, dissociating the epidermis into epidermal cells, and growing the epidermal cells in a tissue culture medium having a pH of from about 5.6 to 5.8.

Process for treating burn victims

Human epidermal cells are grown in tissue culture by separating the epidermis in human skin from the dermis, dissociating the epidermis into epidermal cells, and growing the epidermal cells in a tissue culture medium having a pH of from about 5.6 to about 5.8.

Growing community of inventors

Demarest, NJ, United States of America

Magdalena G Eisinger